Skip to main content
Top
Published in: Clinical and Experimental Medicine 4/2020

01-11-2020 | Macroalbuminuria | Original Article

Decreased serum myonectin concentrations in diabetic nephropathy patients

Authors: Jie Zhang, Wenchao Hu, Peng Lin, Rui Wang

Published in: Clinical and Experimental Medicine | Issue 4/2020

Login to get access

Abstract

Myonectin is a newly discovered myokine correlated with diabetes. Diabetic nephropathy (DN), which is diagnosed according to albuminuria, is one of the most common microvascular complications of diabetes. Albuminuria predisposes to future cardiovascular diseases and mortality. The aim of this study is to assess the association between serum myonectin concentrations with DN. A total of 188 patients with type 2 diabetes (T2DM) and 66 control subjects were enrolled in this investigation. T2DM patients were divided into three groups: normoalbuminuria (n = 84), microalbuminuria (n = 70), and macroalbuminuria (n = 34) according to urine albumin-to-creatinine ratio (ACR). T2DM patients showed lower serum myonectin concentrations compared with the controls. Serum myonectin concentrations were significantly decreased in macroalbuminuria group than in normoalbuminuria and microalbuminuria groups. In addition, microalbuminuria group had decreased serum myonectin concentrations compared with normoalbuminuria group. Logistic regression analysis demonstrated a correlation between serum myonectin and a decreased risk of T2DM and DN. Simply linear regression analysis indicated serum myonectin was negatively correlated body mass index (BMI), total cholesterol, low-density lipoprotein cholesterol, blood urea nitrogen, creatinine, uric acid, and ACR, and positively correlated with glomerular filtration rate, insulin treatment. BMI, ACR, and insulin treatment were still correlated with the serum myonectin after a multiple linear regression analysis. Our investigation indicates serum myonectin is decreased in DN patients and correlated with renal function.
Literature
1.
go back to reference Jansson SP, Fall K, Brus O, et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32:1319–28.CrossRef Jansson SP, Fall K, Brus O, et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32:1319–28.CrossRef
2.
go back to reference Souweine JS, Corbel A, Rigothier C, et al. Interest of albuminuria in nephrology, diabetology and as a marker of cardiovascular risk. Ann Biol Clin (Paris). 2019;77:26–35. Souweine JS, Corbel A, Rigothier C, et al. Interest of albuminuria in nephrology, diabetology and as a marker of cardiovascular risk. Ann Biol Clin (Paris). 2019;77:26–35.
3.
go back to reference Uchida J, Machida Y, Iwai T, et al. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients. J Nephrol. 2011;24:515–21.CrossRef Uchida J, Machida Y, Iwai T, et al. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients. J Nephrol. 2011;24:515–21.CrossRef
4.
go back to reference Perkovic V, Verdon C, Ninomiya T, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis, Version 2. PLoS Med. 2008;5:e207.CrossRef Perkovic V, Verdon C, Ninomiya T, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis, Version 2. PLoS Med. 2008;5:e207.CrossRef
5.
go back to reference Kakio Y, Uchida HA, Takeuchi H, et al. Diabetic nephropathy is associated with frailty in patients with chronic hemodialysis. Geriatr Gerontol Int. 2018;18:1597–602.CrossRef Kakio Y, Uchida HA, Takeuchi H, et al. Diabetic nephropathy is associated with frailty in patients with chronic hemodialysis. Geriatr Gerontol Int. 2018;18:1597–602.CrossRef
6.
go back to reference Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29:1300–6.CrossRef Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29:1300–6.CrossRef
7.
go back to reference Yan ST, Liu JY, Tian H, Li CL, Li J, Shao YH, Shi HY, Liu Y, Gong YP, Fang FS, Sun BR. Clinical and pathological analysis of renal damage in elderly patients with type 2 diabetes mellitus. Clin Exp Med. 2016;16:437–42.CrossRef Yan ST, Liu JY, Tian H, Li CL, Li J, Shao YH, Shi HY, Liu Y, Gong YP, Fang FS, Sun BR. Clinical and pathological analysis of renal damage in elderly patients with type 2 diabetes mellitus. Clin Exp Med. 2016;16:437–42.CrossRef
8.
go back to reference Seldin MM, Peterson JM, Byerly MS, Wei Z, Wong GW. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012;287:11968–80.CrossRef Seldin MM, Peterson JM, Byerly MS, Wei Z, Wong GW. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012;287:11968–80.CrossRef
9.
go back to reference Lim S, Choi SH, Koo BK, et al. Effects of aerobic exercise training on C1q tumor necrosis factor α-related protein isoform 5 (myonectin): association with insulin resistance and mitochondrial DNA density in women. J Clin Endocrinol Metab. 2012;97:E88–93.CrossRef Lim S, Choi SH, Koo BK, et al. Effects of aerobic exercise training on C1q tumor necrosis factor α-related protein isoform 5 (myonectin): association with insulin resistance and mitochondrial DNA density in women. J Clin Endocrinol Metab. 2012;97:E88–93.CrossRef
10.
go back to reference Li Z, Yang YL, Zhu YJ, et al. Circulating serum myonectin levels in obesity and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes; 2019 Jul 24. Li Z, Yang YL, Zhu YJ, et al. Circulating serum myonectin levels in obesity and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes; 2019 Jul 24.
11.
go back to reference Li K, Liao X, Wang K, et al. Myonectin predicts the development of type 2 diabetes. J Clin Endocrinol Metab. 2018;103:139–47.CrossRef Li K, Liao X, Wang K, et al. Myonectin predicts the development of type 2 diabetes. J Clin Endocrinol Metab. 2018;103:139–47.CrossRef
12.
go back to reference Zhang Y, Liu C, Liu J, et al. Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease. Sci Rep. 2020;10:878.CrossRef Zhang Y, Liu C, Liu J, et al. Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease. Sci Rep. 2020;10:878.CrossRef
14.
go back to reference Otaka N, Shibata R, Ohashi K, et al. Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. Circ Res. 2018;123:1326–38.CrossRef Otaka N, Shibata R, Ohashi K, et al. Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. Circ Res. 2018;123:1326–38.CrossRef
15.
go back to reference Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun. 2013;433:359–61.CrossRef Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun. 2013;433:359–61.CrossRef
16.
go back to reference VasanthRao VR, Tan SH, Candasamy M, Bhattamisra SK. Diabetic nephropathy: an update on pathogenesis and drug development. Diabetes Metab Syndr. 2019;13:754–62.CrossRef VasanthRao VR, Tan SH, Candasamy M, Bhattamisra SK. Diabetic nephropathy: an update on pathogenesis and drug development. Diabetes Metab Syndr. 2019;13:754–62.CrossRef
17.
go back to reference Aghadavod E, Khodadadi S, Baradaran A, Nasri P, Bahmani M, Rafieian-Kopaei M. Role of oxidative stress and inflammatory factors in diabetic kidney disease. Iran J Kidney Dis. 2016;10:337–43.PubMed Aghadavod E, Khodadadi S, Baradaran A, Nasri P, Bahmani M, Rafieian-Kopaei M. Role of oxidative stress and inflammatory factors in diabetic kidney disease. Iran J Kidney Dis. 2016;10:337–43.PubMed
18.
go back to reference Barutta F, Bruno G, Grimaldi S, Gruden G. Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine. 2015;48:730–42.CrossRef Barutta F, Bruno G, Grimaldi S, Gruden G. Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine. 2015;48:730–42.CrossRef
19.
go back to reference Peterson JM, Mart R, Bond CE. Effect of obesity and exercise on the expression of the novel myokines, myonectin and fibronectin type III domain containing 5. PeerJ. 2014;2:e605.CrossRef Peterson JM, Mart R, Bond CE. Effect of obesity and exercise on the expression of the novel myokines, myonectin and fibronectin type III domain containing 5. PeerJ. 2014;2:e605.CrossRef
20.
go back to reference Little HC, Rodriguez S, Lei X, et al. Myonectin deletion promotes adipose fat storage and reduces liver steatosis. FASEB J. 2019;33:8666–87.CrossRef Little HC, Rodriguez S, Lei X, et al. Myonectin deletion promotes adipose fat storage and reduces liver steatosis. FASEB J. 2019;33:8666–87.CrossRef
Metadata
Title
Decreased serum myonectin concentrations in diabetic nephropathy patients
Authors
Jie Zhang
Wenchao Hu
Peng Lin
Rui Wang
Publication date
01-11-2020
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 4/2020
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-020-00654-z

Other articles of this Issue 4/2020

Clinical and Experimental Medicine 4/2020 Go to the issue